Compare AbCellera Biologics Inc (ABCL) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Dover Corp — how do they compare? AbCellera Biologics Inc trades at $9.08 (market cap $2.85B), while Dover Corp trades at $208.79 (market cap $28.30B). The key difference: Dover Corp is far larger — about 9.9× AbCellera Biologics Inc's market cap, and Dover Corp pays a 0.99% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DOV | |
|---|---|---|
Market Cap | $2.85B | $28.30B |
Sector | Health | Industrials |
52-Week High | $9.76 | $233.31 |
52-Week Low | $2.78 | $161.16 |
Enterprise Value | $2.45B | $29.80B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Dover Corporation (DOV) trades at $211.13, up 0.14% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $2.74, and the company raised its full-year guidance. A dividend increase to $0.525 per share and the acquisition of Cloeren highlight positive corporate actions. Valuation ratios include a P/E of 25.53 and net income margin of 13.48%, reflecting solid profitability.
The outlook for DOV is positive, driven by earnings momentum, raised guidance, and strategic acquisitions. Risks include exposure to manufacturing cycles and macroeconomic volatility. With 19 buy ratings and a consensus price target of $232.33, Wall Street sees upside potential, though investors should monitor execution on growth initiatives and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
